RAC 2.92% $1.94 race oncology ltd

RAC media coverage, page-1706

  1. 269 Posts.
    lightbulb Created with Sketch. 1043
    Interesting that they have treating the first patient in the EMD AML trial as an upcoming catalyst in H2CY2023…….I thought this trial was put on ice by DCB as he was trying to pivot to multiple R/R AML trials instead as per his revised strategy?

    Since this is paid research by RACE Oncology, @Davisite are you able to clarify if this is up to date and accurate?

 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.